Latest Administration News

4DMedical has rapidly commercialised its CT – VQ™ lung imaging technology following FDA clearance, securing major partnerships and regulatory approvals that position it for significant growth in North America.

Cann Group Limited has reported its first-ever free cash flow positive quarter, following a significant debt restructuring and a $9 million capital raise. Despite a softer quarterly revenue, the company is advancing new product launches and export partnerships, positioning itself for growth.

Alterity Therapeutics has bolstered its Phase 2 data for ATH434 in Multiple System Atrophy and is advancing regulatory plans for a pivotal Phase 3 trial, supported by a robust cash position of A$49.2 million.

Stakk Limited has reported a robust Q2FY26 with record cash receipts and a fortified $15.1 million cash reserve, setting the stage for breakeven in CY26 amid strong Tier-1 client momentum.

Po Valley Energy has adopted its first-ever dividend policy and announced plans to pay a maiden dividend, signalling confidence in its cash flow and future growth prospects.

Actinogen Medical’s pivotal XanaMIA trial for Alzheimer’s disease has received a green light from its independent Data Monitoring Committee to continue, reinforcing confidence in the drug’s safety and efficacy profile.

Antares Metals reported a cash outflow in operating activities for Q2 2025 but bolstered its balance sheet with a $1 million placement, positioning itself for focused exploration in Western Australia.

HeraMED has secured pivotal US commercial agreements and achieved a key Australian regulatory milestone, positioning itself for scalable growth in digital maternity care.

Artrya Limited has converted three US foundation partners into commercial customers, generating its first fee-per-scan revenues, while progressing FDA clearance for its Salix Coronary Flow module and expanding its clinical study network.

Infinity Metals Limited reported a steady cash position of A$2.25 million at the end of December 2025, with operational spending continuing but no new financing activities. The company estimates funding for over five quarters based on current expenditure.

Adheris Health reported a sharp decline in Q2 FY26 revenue but is pushing ahead with leadership changes, cost cuts, and a new digital platform to reshape its future.

Nutritional Growth Solutions reports improved cash flow and cost savings amid leadership changes, setting the stage for renewed growth in FY26.